Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study
暂无分享,去创建一个
F. Jardin | E. Hoster | E. Macintyre | M. Dreyling | M. Cheminant | O. Hermine | V. Ribrag | V. Asnafi | L. Lhermitte | C. Thieblemont | F. Lefrère | S. Chèze | R. Delarue | L. Sanhes | M. Delfau-Larue | A. Trinquand | Stephanie L. Schmit | Adrien Grenier | A. Touzart | C. Derrieux | F. Lefrère | S. Schmit | S. Cheze
[1] M. Boccadoro,et al. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. , 2015, The Journal of molecular diagnostics : JMD.
[2] A. Órfão,et al. New criteria for response assessment: role of minimal residual disease in multiple myeloma. , 2015, Blood.
[3] G. Morgan,et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. , 2015, Blood.
[4] M. Boubaya,et al. Minimal Residual Disease (MRD) By 8-Color Flow Cytometry (Flow-MRD) and IGH Clonospecific Quantitative PCR (ASO RQPCR) Reached Similar Performances for Evaluation of CLL Treatment in a Phase II Clinical Trial: Cross Validation of the Methods , 2014 .
[5] G. Salles,et al. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study , 2014 .
[6] E. Macintyre,et al. Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high‐risk patients , 2014, British journal of haematology.
[7] A. Palumbo,et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders , 2014, Leukemia.
[8] M. Stetler-Stevenson,et al. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. , 2013, Blood.
[9] E. Clappier,et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL , 2013, Leukemia.
[10] G. Salles,et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.
[11] E. Montserrat,et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL , 2013, Leukemia.
[12] M. Schrappe. Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient. , 2012, Hematology. American Society of Hematology. Education Program.
[13] W. Klapper,et al. Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.
[14] A Orfao,et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes , 2012, Leukemia.
[15] W. Klapper,et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. , 2010, Blood.
[16] M. Eriksson,et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Kimby,et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.
[18] W. Klapper,et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations , 2008, Haematologica.
[19] J. Cayuela,et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.
[20] R. Siebert,et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. , 2006, Blood.
[21] Michael L. Wang,et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] E. Hoster,et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] E. Hoster,et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.
[24] A. Delmer,et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. , 2004, Haematologica.
[25] J J Shuster,et al. Minimal residual disease detection in childhood precursor–B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study , 2003, Leukemia.
[26] A Orfao,et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation , 2002, Leukemia.
[27] H Clevers,et al. Leukocyte‐associated immunoglobulin‐like receptor‐1 (LAIR‐1) is differentially expressed during human B cell differentiation and inhibits B cell receptor‐mediated signaling , 1999, European journal of immunology.
[28] F. Behm,et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia , 1999, Leukemia.
[29] A. Hagenbeek,et al. Detection of Minimal Residual Disease in Acute Leukemia by Flow Cytometry a , 1986, Annals of the New York Academy of Sciences.
[30] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.